SavedAdd your journal

Journals / Retina-Vitreus / 2017 / Cilt: 26 - Sayı: 3

Update on experimental animal models in common retinal diseases: Rodents to Zebrafi sh

Yaygın Retina Hastalıklarında Deneysel Hayvan Modellerinde Gelişmeler: Rodentler'den Zebra Balığı'na

Muhammed Necati DEMİR
MEHMET AKİF ACAR
Pages
275–282
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, it is aimed to share information about experimental animal models that can be used for DR, AMD and similar retinal diseases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetic Rethinopathy (DR) and Age-related Macular Degeneration (AMD) are common retinal diseases that can result with visual impairment.
📊
Key Findings & Data:In spite of the new developments in the treatment modalities of these diseases there are stil many ongoing research in patophysiology and treatment.
💡
Conclusion & Impact:In this review, it is aimed to share information about experimental animal models that can be used for DR, AMD and similar retinal diseases.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Diabetic Rethinopathy (DR) and Age-related Macular Degeneration (AMD) are common retinal diseases that can result with visual impairment. In spite of the new developments in the treatment modalities of these diseases there are stil many ongoing research in patophysiology and treatment. The choice of experimental animal model is very important in these researches. There are several models reported in the literature. However, an ideal model has not yet been reached. In this review, it is aimed to share information about experimental animal models that can be used for DR, AMD and similar retinal diseases.

Özet

Diyabetik retinopati (DR) ve Yaşa Bağlı Makula Dejenerasyonu (YBMD) görme kaybı ile sonuçlanabilen yaygın retina hastalıklarıdır. Son yıllarda tedavi sürecinde yaşanan olumlu gelişmelere rağmen, bu ve diğer retina hastalıklarının patofi zyolojisi ve tedavisine yönelik arayışlar halen devam etmektedir. Bu konuda deneysel çalışmalar için uygun deney hayvanı seçimi çok önemlidir. Literatürde çok sayıda hayvan modeli bildirilmekle birlikte ideal modele henüz ulaşılamamıştır. Bu makalede özellikle DR, YBMD ve benzer retina hastalıkları ile ilgili araştırmalarda kullanılabilecek deneysel hayvan modelleri hakkında bilgi sunulmaktadır.

🔖

Cite This Article

DEMİR, M. N., ACAR, M. A. (2017). Update on experimental animal models in common retinal diseases: Rodents to Zebrafi sh. Retina-Vitreus, Cilt: 26 - Sayı: 3, 275–282. https://ajindex.com/articles/307608

References (15)

  1. IDF Diabetes Atlas: 7th edition. Available from: http://www.eatlas.idf.org/; (8 Şubat 2016 tarihinde bu bilgilere ulaşılmıştır.
  2. Wong TY, Mwamburi M, Klein R et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care. 2009; 32(12): 2307-13
  3. Lim LS, Mitchell P, Seddon JM et al. Age-related macular degeneration. Lancet, 2012; 379: 1728-38
  4. Russel WMS and Burch RL. The principles of humane experimental technique (Universities Federation for Animal Welfare). Herts, England, p. 238, 1992
  5. Chatzigeorgiou A, Halapas A, Kalafatakis K, Kamper E. The use of animal models in the study of diabetes mellitus. In vivo. 2009; 23: 245-58
  6. Early Treatment Diabetic Retinopathy Study design and basaline patient characteristics. ETDRS report number 7. Ophthalmology. 1991; 98(5)741-56
  7. Jo DH, Cho CS, Kim JH et al. Animal models of diabetic retinopathy: doors to investigate pathogenesis and potential therapeutics. Journal of Biomedical Science. 2013; 20(38): 1-13
  8. Kim JH, Kim JH, Park JA et al. Blood-neural barrier: intercelluler communication at glio-vascular interface. J Biochem Mol Biol. 2006; 39(4):339-45
  9. Jo DH, Kim JH, Kim JH: How to overcome diabetic retinopathy: focusing on blood-retinal barrier. Immunol Endocr Metab Agents Med Chem. 2012; 12(2):110-7
  10. Saika S, Yamanaka O, Okada Y et al. TGF beta in fi broproliferative diseases in the eye. Front Biosci. 2009; 1:376-90
  11. Mizutani M, Gerhardinger C, Lorenzi M. Muller cell changes in human diabetic retinopathy. Diabetes. 1998; 47(3): 445-9
  12. Barber AJ, Lieth E, Khin SA et al. Neural apoptosis in the retina during experimental and human diabetes: early onset of effect of insülin. Journal of Clinical Investigation. 1998; 102(4): 783-91
  13. Lutty GA, McLeod DS, Merges C et al. Localization of vascular endothelial growth factor in human retina and choroid. Archives of Ophthalmology. 1996; 114(8): 971-7
  14. Lai AK, Lo AC. Animal models of diabetic retinopathy: Summary and Comparison. Journal of Diabetes Research. 2013; 106594: 1-29 15- Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. The Lancet. 2010; 376(9735):124-36 16- Mi XS, Yuan TF, Ding Y et al. Choosing preclinical study models of diabetic retinopathy:key problems for consideration. Drug Design, Development and Therapy.2014; 8:2311-9
  15. Demir MN, Acar U, Sobaci G, et al. The effects of commonly used intravitreal steroids on proliferation index of cill